SS-31 reconstitution calculator
elamipretide - approved as Forzinity®
SS-31 is the rare research peptide that actually crossed the finish line: as elamipretide (Forzinity), it became the first approved therapy for Barth syndrome in 2025. The longevity gray market sells the same molecule for general 'mitochondrial optimization' - an indication no trial has validated, at doses improvised from the rare-disease program.
Enter vial size, water volume, and the dose your provider gave you.
This tool converts the numbers you enter (dose ÷ concentration = volume). It never suggests a dose. The FDA has documented hospitalizations caused by mg / ml / unit conversion errors with vial-and-syringe products - if the readout surprises you, stop and verify with your prescriber or pharmacist.
Questions people actually search
Is SS-31 FDA approved?
The molecule is - as Forzinity (elamipretide), granted accelerated approval in September 2025 for Barth syndrome specifically. Vials sold online for mitochondrial health or longevity are not that product, not that indication, and not approved.
What dose did elamipretide trials use?
The Barth syndrome program (TAZPOWER) used 40 mg once daily subcutaneously - a rare-disease protocol in a monitored population. That number circulating in longevity forums as a general-wellness dose is an extrapolation the evidence doesn't support.
What does SS-31 actually do?
It binds cardiolipin in the inner mitochondrial membrane, aiming to stabilize the electron transport chain. Clinical evidence exists for Barth syndrome (muscle strength); trials in heart failure and mitochondrial myopathy produced mixed results, several missing primary endpoints.